A prospective study of prophylactic long-acting octreotide in high-risk patients undergoing pancreaticoduodenectomy

Jay A. Graham, Lynt B. Johnson, Naddim Haddad, Firas Al-Kawas, John Carroll, Reena Jha, Jason Wong, Dana Maglaris, Shea Mertens, Thomas Fishbein

Research output: Contribution to journalArticle

16 Scopus citations

Abstract

Background: Postoperative pancreatic fistula (postoperative pancreatic fistula [POPF]) is the most common complication after pancreaticoduodenectomy. Despite some studies showing little effect of octreotide in unselected patients, we hypothesized that in high-risk patients depot octreotide may reduce the risk of POPF. Methods: Sixty-eight patients were prospectively evaluated for inclusion in the current study. Two groups were identified: pancreatic ducts ≤3 mm (high risk) and those with ducts >3 mm (low risk). Thirty-two patients were low risk, whereas 36 patients were high risk. High-risk patients were treated preoperatively with depot octreotide and begun on an intravenous drip for 24 hours. Low-risk patients underwent pancreaticoduodenectomy without pharmacologic intervention. In contrast, the control cohort represents 106 retrospectively analyzed patients who underwent a pancreaticoduodenectomy without depot octreotide injection without regard to low- or high-risk status. Results: Overall, POPF was 11 of 68 (16%). Nine of 36 high risk patients treated with depot octreotide developed POPF (25%), and 2 of 32 low risk patients developed POPF (6%). In the control cohort of high-risk patients, 9 of 44 (20%) and 3 of 62 (5%) low-risk patients developed POPF (P = .628 when comparing the development of POPF in high-risk patients with or without pharmacologic intervention). Conclusions: Prophylactic use of depot octreotide in high-risk patients does not result in reduced incidence of POPF. Duct size has a significant impact on the occurrence of POPF.

Original languageEnglish (US)
Pages (from-to)481-485
Number of pages5
JournalAmerican Journal of Surgery
Volume201
Issue number4
DOIs
StatePublished - Apr 1 2011
Externally publishedYes

    Fingerprint

Keywords

  • Duct size
  • Octreotide
  • Pancreatic fistula
  • Pancreatoduodenectomy

ASJC Scopus subject areas

  • Surgery

Cite this

Graham, J. A., Johnson, L. B., Haddad, N., Al-Kawas, F., Carroll, J., Jha, R., Wong, J., Maglaris, D., Mertens, S., & Fishbein, T. (2011). A prospective study of prophylactic long-acting octreotide in high-risk patients undergoing pancreaticoduodenectomy. American Journal of Surgery, 201(4), 481-485. https://doi.org/10.1016/j.amjsurg.2010.06.038